The current first-line recommendations for metastatic liver cancer were multiple kinase inhibitors (sorafenib) and systemic anti-programmed cell death protein-1 inhibitors (nivolumab and pembrolizumab) for hepatocellular carcinoma [5, 20, 21]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.